News

Bayer and NextRNA Therapeutics, a biotechnology company, announced that they would be working together to create a new type of small molecule cancer drug. The two companies agreed to a deal that could be worth over $500 million. The two...

The capacity of a cell line to create a biologic that is both safe and stable in large numbers may be considerably improved by the use of a variety of procedures by those who develop pharmaceuticals. On the other...

The North American nuclear medicine market was estimated to be worth USD 2.05 billion in 2023 and is expected to develop rapidly over the next few years, with a compound annual growth rate (CAGR) of 9.90% through 2029. Within the...

This summer, Bayer officials made sure Fierce understood that the company's desire for deals hasn't been stifled by a group-wide reorganization. Its most recent partnership aimed at treating cancer indicates that Bayer has, in fact, not lost interest in...

The most recent trial of a new antibody drug that goes on to deliver potent chemotherapy that too directly to the cancer cells for patients with advanced or recurrent endometrial cancer has gone a notch up to be studied...

Duality Biotherapeutics from China has gone ahead and filed paperwork as far as a Hong Kong IPO is concerned, thereby looking out for an undisclosed sum so as to power a broad pipeline when it comes to antibody conjugates...

In a recent development taking place in the last week of August 2024, Siemens Healthineers has gone ahead and agreed to pay over 200 million euros, which is equivalent to $223 million, to purchase a part of the radiopharmaceutical...